Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,471 across all filing types
Latest filing 2021-11-08 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details repurchases of shares on various dates, quantities, and prices, confirming compliance with listing rules. The content focuses on share repurchase activities and changes in issued shares, with no financial statements or earnings data. This matches the description of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length is over 12,000 characters and contains detailed transactional data, not just an announcement or certification. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2021-11-08 English
ANNOUNCEMENT - INSIDE INFORMATION - EXCLUSIVE AND WORLDWIDE LICENSE AGREEMENT OUTSIDE GREATER CHINA WITH SUZHOU ALPHAMAB FOR ASC22 (ENVAFOLIMAB) TO TREAT HEPATITIS B AND OTHER VIRAL DISEASES
Regulatory Filings Classification · 95% confidence The document is an announcement made pursuant to the Listing Rules of the Hong Kong Stock Exchange and the Inside Information Provisions under the Securities and Futures Ordinance. It details a license agreement between Ascletis Pharma and Suzhou Alphamab for a drug candidate ASC22. The content focuses on the terms of the license, clinical trial progress, and strategic implications. There are no financial statements, no detailed financial performance data, nor is this a transcript or presentation. The document is an official announcement of a material business development (license agreement) and inside information disclosure. It is not a full report, earnings release, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and inside information disclosures that do not fit other specific categories.
2021-11-08 English
VERY SUBSTANTIAL DISPOSAL AND VERY SUBSTANTIAL ACQUISITION IN RELATION TO LAND RESUMPTION
Capital/Financing Update Classification · 95% confidence The document is an announcement from World Houseware (Holdings) Limited regarding a very substantial disposal and acquisition related to land resumption in Shenzhen, PRC. It details an agreement with local government authorities about land compensation, replacement land, monetary compensation, and timelines for relocation and construction. The announcement includes detailed financial figures, valuation reports, and the impact on the company's operations. It is clearly an announcement of a significant transaction involving asset disposal and acquisition, referencing compliance with Listing Rules and shareholder approval at an EGM. The document is not a full financial report, audit report, or earnings release, nor is it a proxy statement or voting result. It is a regulatory announcement about a major transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to significant asset transactions and capital structure changes due to land disposal and acquisition.
2021-11-05 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details repurchases of shares on various dates, including quantities and prices, and confirms compliance with listing rules. The content focuses on share repurchase activities and changes in issued shares, with no financial statements or earnings data. This matches the description of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length is substantial and contains detailed transactional data, not just an announcement or certification. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2021-11-05 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return (Equity issuer - changes in issued share capital and/or share buybacks)' and contains detailed information about share repurchases by Ascletis Pharma Inc. It includes dates, number of shares repurchased, prices, and confirmations related to compliance with listing rules on the Stock Exchange of Hong Kong. The document is a regulatory disclosure about share capital changes and share buybacks, not a financial report or earnings release. It fits the description of a Transaction in Own Shares (POS) filing, which reports company buybacks or sales of its own shares. The document length is over 12,000 characters and contains substantive data, confirming it is the report itself, not just an announcement of a report.
2021-11-04 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details repurchases of shares on various dates, quantities, and prices, confirming compliance with listing rules of the Stock Exchange of Hong Kong. The content focuses on share repurchase activities and confirmations by the company secretary. There are no financial statements or earnings data, nor is this a report or presentation. The document is a regulatory disclosure about share repurchases, fitting the definition of a Transaction in Own Shares (POS) filing, which reports company buybacks of its own shares.
2021-11-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.